Elan Pharma International Ltd - Net Worth and Insider Trading

Elan Pharma International Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Elan Pharma International Ltd owns 4 companies in total, including Proteostasis Therapeutics Inc (PTI) , Lipocine Inc (LPCN) , and Yumanity Therapeutics Inc (YMTX) among others .

Click here to see the complete history of Elan Pharma International Ltd’s form 4 insider trades.

Insider Ownership Summary of Elan Pharma International Ltd

Ticker	Comapny	Transaction Date	Type of Owner
PTI	Proteostasis Therapeutics Inc	2016-02-10	10 percent owner
LPCN	Lipocine Inc	2013-07-24	10 percent owner & other: (1)
YMTX	Yumanity Therapeutics Inc	2016-02-10	10 percent owner
		2016-02-10	10 percent owner

Elan Pharma International Ltd Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Elan Pharma International Ltd Ownership Network

Ownership Network List of Elan Pharma International Ltd

No Data

Ownership Network Relation of Elan Pharma International Ltd

Elan Pharma International Ltd Owned Company Details

What does Proteostasis Therapeutics Inc do?

Who are the key executives at Proteostasis Therapeutics Inc?

Elan Pharma International Ltd is the 10 percent owner of Proteostasis Therapeutics Inc. Other key executives at Proteostasis Therapeutics Inc include Interim Head of Finance Michael Alfieri , Chief Scientific Officer Benito Munoz , and director & President and CEO Meenu Chhabra .

Proteostasis Therapeutics Inc (PTI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Proteostasis Therapeutics Inc (PTI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Proteostasis Therapeutics Inc (PTI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Proteostasis Therapeutics Inc (PTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Proteostasis Therapeutics Inc Insider Transactions

No Available Data

What does Lipocine Inc do?

Who are the key executives at Lipocine Inc?

Elan Pharma International Ltd is the 10 percent owner & other: (1) of Lipocine Inc. Other key executives at Lipocine Inc include director & President and CEO Mahesh V. Patel , Chief Medical Officer George Nomikos , and Principal Accounting Officer Krista Fogarty .

Lipocine Inc (LPCN) Insider Trades Summary

Over the past 18 months, Elan Pharma International Ltd made no insider transaction in Lipocine Inc (LPCN). Other recent insider transactions involving Lipocine Inc (LPCN) include a net purchase of 8,706 shares made by Mahesh V. Patel ,

In summary, during the past 3 months, insiders sold 0 shares of Lipocine Inc (LPCN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Lipocine Inc (LPCN) were sold and 8,706 shares were bought by its insiders, resulting in a net purchase of 8,706 shares.

Lipocine Inc (LPCN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lipocine Inc Insider Transactions

No Available Data

What does Yumanity Therapeutics Inc do?

Who are the key executives at Yumanity Therapeutics Inc?

Elan Pharma International Ltd is the 10 percent owner of Yumanity Therapeutics Inc. Other key executives at Yumanity Therapeutics Inc include director & Chief Executive Officer Shawn Iadonato , Chief Scientific Officer Thierry Guillaudeux , and Chief Financial Officer Keith Baker .

Yumanity Therapeutics Inc (YMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Yumanity Therapeutics Inc (YMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Yumanity Therapeutics Inc (YMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Yumanity Therapeutics Inc (YMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Yumanity Therapeutics Inc Insider Transactions

No Available Data

What does Kineta Inc do?

Who are the key executives at Kineta Inc?

Elan Pharma International Ltd is the 10 percent owner of Kineta Inc. Other key executives at Kineta Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Kineta Inc (KANT) Insider Trades Summary

Over the past 18 months, Elan Pharma International Ltd made no insider transaction in Kineta Inc (KANT). Other recent insider transactions involving Kineta Inc (KANT) include a net purchase of 7,250 shares made by Raymond J. Bartoszek , a net purchase of 15,000 shares made by Shawn Iadonato , and a net purchase of 10,000 shares made by Keith Baker .

In summary, during the past 3 months, insiders sold 0 shares of Kineta Inc (KANT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kineta Inc (KANT) were sold and 50,250 shares were bought by its insiders, resulting in a net purchase of 50,250 shares.

Kineta Inc (KANT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kineta Inc Insider Transactions

No Available Data

Elan Pharma International Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Elan Pharma International Ltd. You might contact Elan Pharma International Ltd via mailing address: 515 Eastern Avenue, Allegan Mi 49010.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.